Sep 7, 2017

The public should have a say in what a drug is worth

From our Expert Voices conversation on drug pricing.

Setting a "fair price" for a new drug is challenging but not impossible. Because we confer to manufacturers of new drugs a time-limited monopoly, the public has a legitimate claim to participating in the price-setting process. However, today, some aspects of it — like the rebates private insurers receive from manufacturers — are hidden from view.

Another approach: The Institute for Clinical and Economic Review (ICER) recommends prices based on drugs' clinical effectiveness relative to alternative treatments (and the strength of evidence for it), cost-effectiveness, and the extent to which prices are sustainable with health care program budgets. The process is far from formulaic; importantly, it takes account of additional factors like whether treatment outcomes reduce disparities across patient groups or facilitates greater productivity.

ICER's approach isn't perfect, but it is at least is open and includes public input, which is more than can be said for the rebates manufacturers offer insurers and pharmacy benefits managers.

The bottom line: If nothing else, a price for a monopoly drug will not widely be accepted as "fair" if it is arrived at in secret.

Other voices in the conversation:

Go deeper

Coronavirus spreads to more countries, and U.S. ups its case count

Data: The Center for Systems Science and Engineering at Johns Hopkins, the CDC, and China's Health Ministry. Note: China numbers are for the mainland only and U.S. numbers include repatriated citizens.

The novel coronavirus continues to spread to more nations, and the U.S. reports a doubling of its confirmed cases to 34 — while noting those are mostly due to repatriated citizens, emphasizing there's no "community spread" yet in the U.S. Meanwhile, Italy reported its first virus-related death on Friday.

The big picture: COVID-19 has now killed at least 2,359 people and infected more than 77,000 others, mostly in mainland China. New countries to announce infections recently include Israel, Lebanon and Iran.

Go deeperArrowUpdated 5 hours ago - Health

Wells Fargo agrees to pay $3 billion to settle consumer abuse charges

Clients use an ATM at a Wells Fargo Bank in Los Angeles, Calif. Photo: Ronen Tivony/SOPA Images/LightRocket via Getty Images

Wells Fargo agreed to a pay a combined $3 billion to the Justice Department and the Securities and Exchange Commission on Friday for opening millions of fake customer accounts between 2002 and 2016, the SEC said in a press release.

The big picture: The fine "is among the largest corporate penalties reached during the Trump administration," the Washington Post reports.